SpyGlass Pharma（SGP）株式概要スパイグラス・ファーマ社は、慢性的な眼疾患患者のための治療と薬物送達を提供するバイオ医薬品会社である。 詳細SGP ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析今後3年間の収益は年平均24.5%減少すると予測されている。 収益が 100 万ドル未満 ( $0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るSGP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,132 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG490,132 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$22.52該当なし内在価値ディスカウントEst. Revenue$PastFuture-45m172016201920222025202620282031Revenue US$17.2Earnings US$2.5AdvancedSet Fair ValueView all narrativesSpyGlass Pharma, Inc. 競合他社Relmada TherapeuticsSymbol: NasdaqCM:RLMDMarket cap: US$682.8mCorMedixSymbol: NasdaqGM:CRMDMarket cap: US$680.2mContineum TherapeuticsSymbol: NasdaqGS:CTNMMarket cap: US$577.6mTilray BrandsSymbol: NasdaqGS:TLRYMarket cap: US$523.7m価格と性能株価の高値、安値、推移の概要SpyGlass Pharma過去の株価現在の株価US$22.5252週高値US$32.4452週安値US$17.06ベータ01ヶ月の変化25.32%3ヶ月変化8.53%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-14.70%最新ニュースお知らせ • Jun 15SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General CounselSpyGlass Pharma, Inc. announced the appointment of Shannon Treviño as General Counsel. Ms. Treviño is a strategic legal executive with experience in corporate, M&A, and securities law in the healthcare industry. Most recently serving as General Counsel and Corporate Secretary at Inari Medical, Ms. Treviño oversaw the legal and compliance functions and helped guide the company through its $4.9 billion acquisition by Stryker. She also was instrumental in Inari's acquisition of LimFlow and its subsequent integration. Prior to Inari, she served as an attorney at Sugg Law Group, where she advised early and growth-stage companies on governance, commercial contracts, capital formation, and M&A transactions. She also spent eight years as a Clinical Professor and Director of the Transactional Lawyering Institute at Loyola Marymount University’s Law School, where she taught courses on venture capital, M&A negotiations, and in-house lawyering, and co-authored two editions of a textbook on startup financing. Earlier in her career, Shannon was a corporate attorney at Latham & Watkins LLP from 2006 to 2015. Ms. Treviño holds a J.D., summa cum laude, from LMU Loyola Law School and an A.B. from Princeton University.お知らせ • Mar 10SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results For Its Innovative BIM-IOL SystemSpyGlass Pharma, Inc. announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract. A total of 104 patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) and 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL from Alcon, Bausch + Lomb or Johnson & Johnson with twice-daily administration of timolol eye drops as the control group (N=30). At 12 months, the BIM-IOL System achieved: Evaluable patients achieved a 34% and 42% reduction in mean IOP from baseline in the 78-mcg and 39-mcg dose groups, respectively, compared to a 35% reduction in the control group at 8 a.m. Results were similar at the 10 a.m. timepoint. 98% of evaluable patients (48 of 49) in the 78-mcg dose group and 96% of evaluable patients (22 of 23) in the 39-mcg dose group were free from all topical IOP-lowering medications. Evaluable patients (N=72) demonstrated vision improvement, 100% reaching 20/32 or better best corrected distance visual acuity (BCDVA) and mean BCDVA of 86 letters (equivalent to 20/20 vision). Adverse event (AE) rates were similar across the 78-mcg (41.2%), 39-mcg (43.5%), and control (36.7%) groups. No serious ocular AEs were observed. In January 2026, SpyGlass Pharma announced that the first patients were randomized in two identical registrational Phase 3 trials of the 78-mcg dose of the BIM-IOL System. The Phase 3 trials are largely consistent in trial design with the SpyGlass Pharma Phase 1/2 trial with minor protocol modifications intended to improve consistency across trial arms. The Phase 1/2 trial is a prospective, multicenter, randomized, double-masked, controlled clinical trial evaluating the safety and efficacy of the innovative BIM-IOL System in patients with OAG or OHT undergoing cataract surgery. A total of 104 evaluable patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) with daily administration of artificial tear drops, 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL with twice-daily administration of timolol eye drops as the control group (N=30). The primary endpoint is mean IOP reduction from baseline at two time points for each follow-up visit at the 2 Weeks, 6 Weeks, and 3 Months. Secondary endpoints include mean IOP reduction from baseline, mean IOP, time to reintroduction and number of IOP-lowering medications, and improvement of visual performance. The trial also includes typical safety assessments for both medication and IOL. SpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System is designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT. The company continues long-term follow-up of patients in both the first-in-human trial and Phase 1/2 trial as well as patient enrollment in ongoing Phase 3 clinical trials. SpyGlass plans to work with the FDA to advance the program through 505(b)(2) New Drug Application (NDA) submission and ultimately to potential commercial approval.お知らせ • Feb 06SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million.SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,375,000 Price\Range: $16 Transaction Features: Sponsor Backed Offering最新情報をもっと見るRecent updatesお知らせ • Jun 15SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General CounselSpyGlass Pharma, Inc. announced the appointment of Shannon Treviño as General Counsel. Ms. Treviño is a strategic legal executive with experience in corporate, M&A, and securities law in the healthcare industry. Most recently serving as General Counsel and Corporate Secretary at Inari Medical, Ms. Treviño oversaw the legal and compliance functions and helped guide the company through its $4.9 billion acquisition by Stryker. She also was instrumental in Inari's acquisition of LimFlow and its subsequent integration. Prior to Inari, she served as an attorney at Sugg Law Group, where she advised early and growth-stage companies on governance, commercial contracts, capital formation, and M&A transactions. She also spent eight years as a Clinical Professor and Director of the Transactional Lawyering Institute at Loyola Marymount University’s Law School, where she taught courses on venture capital, M&A negotiations, and in-house lawyering, and co-authored two editions of a textbook on startup financing. Earlier in her career, Shannon was a corporate attorney at Latham & Watkins LLP from 2006 to 2015. Ms. Treviño holds a J.D., summa cum laude, from LMU Loyola Law School and an A.B. from Princeton University.お知らせ • Mar 10SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results For Its Innovative BIM-IOL SystemSpyGlass Pharma, Inc. announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract. A total of 104 patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) and 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL from Alcon, Bausch + Lomb or Johnson & Johnson with twice-daily administration of timolol eye drops as the control group (N=30). At 12 months, the BIM-IOL System achieved: Evaluable patients achieved a 34% and 42% reduction in mean IOP from baseline in the 78-mcg and 39-mcg dose groups, respectively, compared to a 35% reduction in the control group at 8 a.m. Results were similar at the 10 a.m. timepoint. 98% of evaluable patients (48 of 49) in the 78-mcg dose group and 96% of evaluable patients (22 of 23) in the 39-mcg dose group were free from all topical IOP-lowering medications. Evaluable patients (N=72) demonstrated vision improvement, 100% reaching 20/32 or better best corrected distance visual acuity (BCDVA) and mean BCDVA of 86 letters (equivalent to 20/20 vision). Adverse event (AE) rates were similar across the 78-mcg (41.2%), 39-mcg (43.5%), and control (36.7%) groups. No serious ocular AEs were observed. In January 2026, SpyGlass Pharma announced that the first patients were randomized in two identical registrational Phase 3 trials of the 78-mcg dose of the BIM-IOL System. The Phase 3 trials are largely consistent in trial design with the SpyGlass Pharma Phase 1/2 trial with minor protocol modifications intended to improve consistency across trial arms. The Phase 1/2 trial is a prospective, multicenter, randomized, double-masked, controlled clinical trial evaluating the safety and efficacy of the innovative BIM-IOL System in patients with OAG or OHT undergoing cataract surgery. A total of 104 evaluable patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) with daily administration of artificial tear drops, 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL with twice-daily administration of timolol eye drops as the control group (N=30). The primary endpoint is mean IOP reduction from baseline at two time points for each follow-up visit at the 2 Weeks, 6 Weeks, and 3 Months. Secondary endpoints include mean IOP reduction from baseline, mean IOP, time to reintroduction and number of IOP-lowering medications, and improvement of visual performance. The trial also includes typical safety assessments for both medication and IOL. SpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System is designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT. The company continues long-term follow-up of patients in both the first-in-human trial and Phase 1/2 trial as well as patient enrollment in ongoing Phase 3 clinical trials. SpyGlass plans to work with the FDA to advance the program through 505(b)(2) New Drug Application (NDA) submission and ultimately to potential commercial approval.お知らせ • Feb 06SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million.SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,375,000 Price\Range: $16 Transaction Features: Sponsor Backed Offering株主還元SGPUS PharmaceuticalsUS 市場7D17.6%-2.0%0.7%1Yn/a44.4%20.6%株主還元を見る業界別リターン: SGPがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: SGP US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is SGP's price volatile compared to industry and market?SGP volatilitySGP Average Weekly Movement9.9%Pharmaceuticals Industry Average Movement9.3%Market Average Movement7.3%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.2%安定した株価: SGP 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のSGPのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト201968Patrick Mooneywww.spyglasspharma.comスパイグラス・ファーマ社は、慢性的な眼疾患を抱える患者に治療と薬物送達を提供するバイオ医薬品会社として事業を展開している。同社はビマトプロスト・ドラッグパッド眼内レンズシステム（BIM-眼内レンズシステム）を開発している。このシステムには、眼内レンズ（IOL）に装着される新規かつ独自の薬物パッドが含まれ、患者の眼圧上昇を抑えるために白内障手術の際に定期的に移植されるように設計されている。また、眼内レンズを使用しない、リング状のビマトプロスト徐放性インプラントも開発している。SpyGlass Pharma, Inc.の前身はSpyGlass Ophthalmics, Inc.で、2021年4月にSpyGlass Pharma, Inc.に社名変更した。同社は2019年に法人化され、カリフォルニア州アリソビエホを拠点としている。もっと見るSpyGlass Pharma, Inc. 基礎のまとめSpyGlass Pharma の収益と売上を時価総額と比較するとどうか。SGP 基礎統計学時価総額US$671.01m収益（TTM）-US$44.86m売上高(TTM)n/a0.0xP/Sレシオ-16.8xPER（株価収益率SGP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SGP 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$44.86m収益-US$44.86m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.34グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%SGP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/10 12:38終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SpyGlass Pharma, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Yigal NochomovitzCitigroup IncYi ChenH.C. Wainwright & Co.Yuchen DingJefferies LLC2 その他のアナリストを表示
お知らせ • Jun 15SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General CounselSpyGlass Pharma, Inc. announced the appointment of Shannon Treviño as General Counsel. Ms. Treviño is a strategic legal executive with experience in corporate, M&A, and securities law in the healthcare industry. Most recently serving as General Counsel and Corporate Secretary at Inari Medical, Ms. Treviño oversaw the legal and compliance functions and helped guide the company through its $4.9 billion acquisition by Stryker. She also was instrumental in Inari's acquisition of LimFlow and its subsequent integration. Prior to Inari, she served as an attorney at Sugg Law Group, where she advised early and growth-stage companies on governance, commercial contracts, capital formation, and M&A transactions. She also spent eight years as a Clinical Professor and Director of the Transactional Lawyering Institute at Loyola Marymount University’s Law School, where she taught courses on venture capital, M&A negotiations, and in-house lawyering, and co-authored two editions of a textbook on startup financing. Earlier in her career, Shannon was a corporate attorney at Latham & Watkins LLP from 2006 to 2015. Ms. Treviño holds a J.D., summa cum laude, from LMU Loyola Law School and an A.B. from Princeton University.
お知らせ • Mar 10SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results For Its Innovative BIM-IOL SystemSpyGlass Pharma, Inc. announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract. A total of 104 patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) and 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL from Alcon, Bausch + Lomb or Johnson & Johnson with twice-daily administration of timolol eye drops as the control group (N=30). At 12 months, the BIM-IOL System achieved: Evaluable patients achieved a 34% and 42% reduction in mean IOP from baseline in the 78-mcg and 39-mcg dose groups, respectively, compared to a 35% reduction in the control group at 8 a.m. Results were similar at the 10 a.m. timepoint. 98% of evaluable patients (48 of 49) in the 78-mcg dose group and 96% of evaluable patients (22 of 23) in the 39-mcg dose group were free from all topical IOP-lowering medications. Evaluable patients (N=72) demonstrated vision improvement, 100% reaching 20/32 or better best corrected distance visual acuity (BCDVA) and mean BCDVA of 86 letters (equivalent to 20/20 vision). Adverse event (AE) rates were similar across the 78-mcg (41.2%), 39-mcg (43.5%), and control (36.7%) groups. No serious ocular AEs were observed. In January 2026, SpyGlass Pharma announced that the first patients were randomized in two identical registrational Phase 3 trials of the 78-mcg dose of the BIM-IOL System. The Phase 3 trials are largely consistent in trial design with the SpyGlass Pharma Phase 1/2 trial with minor protocol modifications intended to improve consistency across trial arms. The Phase 1/2 trial is a prospective, multicenter, randomized, double-masked, controlled clinical trial evaluating the safety and efficacy of the innovative BIM-IOL System in patients with OAG or OHT undergoing cataract surgery. A total of 104 evaluable patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) with daily administration of artificial tear drops, 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL with twice-daily administration of timolol eye drops as the control group (N=30). The primary endpoint is mean IOP reduction from baseline at two time points for each follow-up visit at the 2 Weeks, 6 Weeks, and 3 Months. Secondary endpoints include mean IOP reduction from baseline, mean IOP, time to reintroduction and number of IOP-lowering medications, and improvement of visual performance. The trial also includes typical safety assessments for both medication and IOL. SpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System is designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT. The company continues long-term follow-up of patients in both the first-in-human trial and Phase 1/2 trial as well as patient enrollment in ongoing Phase 3 clinical trials. SpyGlass plans to work with the FDA to advance the program through 505(b)(2) New Drug Application (NDA) submission and ultimately to potential commercial approval.
お知らせ • Feb 06SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million.SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,375,000 Price\Range: $16 Transaction Features: Sponsor Backed Offering
お知らせ • Jun 15SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General CounselSpyGlass Pharma, Inc. announced the appointment of Shannon Treviño as General Counsel. Ms. Treviño is a strategic legal executive with experience in corporate, M&A, and securities law in the healthcare industry. Most recently serving as General Counsel and Corporate Secretary at Inari Medical, Ms. Treviño oversaw the legal and compliance functions and helped guide the company through its $4.9 billion acquisition by Stryker. She also was instrumental in Inari's acquisition of LimFlow and its subsequent integration. Prior to Inari, she served as an attorney at Sugg Law Group, where she advised early and growth-stage companies on governance, commercial contracts, capital formation, and M&A transactions. She also spent eight years as a Clinical Professor and Director of the Transactional Lawyering Institute at Loyola Marymount University’s Law School, where she taught courses on venture capital, M&A negotiations, and in-house lawyering, and co-authored two editions of a textbook on startup financing. Earlier in her career, Shannon was a corporate attorney at Latham & Watkins LLP from 2006 to 2015. Ms. Treviño holds a J.D., summa cum laude, from LMU Loyola Law School and an A.B. from Princeton University.
お知らせ • Mar 10SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results For Its Innovative BIM-IOL SystemSpyGlass Pharma, Inc. announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract. A total of 104 patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) and 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL from Alcon, Bausch + Lomb or Johnson & Johnson with twice-daily administration of timolol eye drops as the control group (N=30). At 12 months, the BIM-IOL System achieved: Evaluable patients achieved a 34% and 42% reduction in mean IOP from baseline in the 78-mcg and 39-mcg dose groups, respectively, compared to a 35% reduction in the control group at 8 a.m. Results were similar at the 10 a.m. timepoint. 98% of evaluable patients (48 of 49) in the 78-mcg dose group and 96% of evaluable patients (22 of 23) in the 39-mcg dose group were free from all topical IOP-lowering medications. Evaluable patients (N=72) demonstrated vision improvement, 100% reaching 20/32 or better best corrected distance visual acuity (BCDVA) and mean BCDVA of 86 letters (equivalent to 20/20 vision). Adverse event (AE) rates were similar across the 78-mcg (41.2%), 39-mcg (43.5%), and control (36.7%) groups. No serious ocular AEs were observed. In January 2026, SpyGlass Pharma announced that the first patients were randomized in two identical registrational Phase 3 trials of the 78-mcg dose of the BIM-IOL System. The Phase 3 trials are largely consistent in trial design with the SpyGlass Pharma Phase 1/2 trial with minor protocol modifications intended to improve consistency across trial arms. The Phase 1/2 trial is a prospective, multicenter, randomized, double-masked, controlled clinical trial evaluating the safety and efficacy of the innovative BIM-IOL System in patients with OAG or OHT undergoing cataract surgery. A total of 104 evaluable patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) with daily administration of artificial tear drops, 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL with twice-daily administration of timolol eye drops as the control group (N=30). The primary endpoint is mean IOP reduction from baseline at two time points for each follow-up visit at the 2 Weeks, 6 Weeks, and 3 Months. Secondary endpoints include mean IOP reduction from baseline, mean IOP, time to reintroduction and number of IOP-lowering medications, and improvement of visual performance. The trial also includes typical safety assessments for both medication and IOL. SpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). The BIM-IOL System is designed to consistently deliver multiple years of bimatoprost, a prostaglandin analog approved for topical use by the U.S. Food and Drug Administration (FDA) in 2001, for the reduction of elevated IOP in patients with OAG or OHT. The company continues long-term follow-up of patients in both the first-in-human trial and Phase 1/2 trial as well as patient enrollment in ongoing Phase 3 clinical trials. SpyGlass plans to work with the FDA to advance the program through 505(b)(2) New Drug Application (NDA) submission and ultimately to potential commercial approval.
お知らせ • Feb 06SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million.SpyGlass Pharma, Inc. has completed an IPO in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,375,000 Price\Range: $16 Transaction Features: Sponsor Backed Offering
